BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 18388514)

  • 1. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P; Kingsley GH; Scott DL
    Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
    Kitahara K; Kawai S
    Curr Opin Rheumatol; 2007 May; 19(3):238-45. PubMed ID: 17414949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of rheumatoid arthritis].
    Babić-Naglić D
    Reumatizam; 2003; 50(2):22-7. PubMed ID: 15098369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination therapy of disease-modifying antirheumatic drugs(DMARDs) in rheumatoid arthritis].
    Kobayashi S; Kanai Y
    Nihon Rinsho; 2002 Dec; 60(12):2351-6. PubMed ID: 12510361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug.
    Prescrire Int; 2001 Apr; 10(52):36-9. PubMed ID: 11718154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS; Taylor WJ;
    J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis.
    Soriano ER
    J Rheumatol Suppl; 2012 Jul; 89():67-70. PubMed ID: 22751597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination therapy in rheumatoid arthritis].
    Johnsen V; Førre Ø; Haga HJ; Kvien TK; Mikkelsen K; Nordvåg BY; Rødevand E
    Tidsskr Nor Laegeforen; 2003 May; 123(11):1511-3. PubMed ID: 12822010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH; Whelton A
    Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BeSt story: on strategy trials in rheumatoid arthritis.
    Klarenbeek NB; Allaart CF; Kerstens PJ; Huizinga TW; Dijkmans BA
    Curr Opin Rheumatol; 2009 May; 21(3):291-8. PubMed ID: 19318946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
    Taniguchi A; Urano W; Tanaka E; Furihata S; Kamitsuji S; Inoue E; Yamanaka M; Yamanaka H; Kamatani N
    Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
    O'Dell JR; Haire CE; Erikson N; Drymalski W; Palmer W; Eckhoff PJ; Garwood V; Maloley P; Klassen LW; Wees S; Klein H; Moore GF
    N Engl J Med; 1996 May; 334(20):1287-91. PubMed ID: 8609945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
    Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
    Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
    Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.